The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2024-08-10 DOI:10.1515/med-2024-0974

Ruigang Dou, Rongfeng Liu, Peng Su, Xiaohui Yu, Yanzhao Xu

{"title":"The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma","authors":"Ruigang Dou, Rongfeng Liu, Peng Su, Xiaohui Yu, Yanzhao Xu","doi":"10.1515/med-2024-0974","DOIUrl":null,"url":null,"abstract":"Gap junction protein beta 3 (GJB3) has been reported as a tumor suppressor in most tumors. However, its role in lung adenocarcinoma (LUAD) remains unknown. The purpose of this study is to explore the role of GJB3 in the prognosis and tumor microenvironment of LUAD patients. The data used in this study were acquired from The Cancer Genome Atlas, Gene Expression Omnibus, and imvigor210 cohorts. We found that GJB3 expression was increased in LUAD patients and correlated with LUAD stages. LUAD patients with high GJB3 expression exhibited a worse prognosis. A total of 164 pathways were significantly activated in the GJB3 high group. GJB3 expression was positively associated with nine transcription factors and might be negatively regulated by hsa-miR-6511b-5p. Finally, we found that immune cell infiltration and immune checkpoint expression were different between the GJB3 high and GJB3 low groups. In summary. GJB3 demonstrated high expression levels in LUAD patients, and those with elevated GJB3 expression displayed unfavorable prognoses. Additionally, there was a correlation between GJB3 and immune cell infiltration, as well as immune checkpoint expression in LUAD patients","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"11 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-0974","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Gap junction protein beta 3 (GJB3) has been reported as a tumor suppressor in most tumors. However, its role in lung adenocarcinoma (LUAD) remains unknown. The purpose of this study is to explore the role of GJB3 in the prognosis and tumor microenvironment of LUAD patients. The data used in this study were acquired from The Cancer Genome Atlas, Gene Expression Omnibus, and imvigor210 cohorts. We found that GJB3 expression was increased in LUAD patients and correlated with LUAD stages. LUAD patients with high GJB3 expression exhibited a worse prognosis. A total of 164 pathways were significantly activated in the GJB3 high group. GJB3 expression was positively associated with nine transcription factors and might be negatively regulated by hsa-miR-6511b-5p. Finally, we found that immune cell infiltration and immune checkpoint expression were different between the GJB3 high and GJB3 low groups. In summary. GJB3 demonstrated high expression levels in LUAD patients, and those with elevated GJB3 expression displayed unfavorable prognoses. Additionally, there was a correlation between GJB3 and immune cell infiltration, as well as immune checkpoint expression in LUAD patients

查看原文本刊更多论文

GJB3 与肺腺癌的预后、免疫细胞浸润和治疗反应有关

据报道，间隙连接蛋白 beta 3（GJB3）在大多数肿瘤中都是一种肿瘤抑制因子。然而，它在肺腺癌（LUAD）中的作用仍然未知。本研究旨在探讨 GJB3 在 LUAD 患者的预后和肿瘤微环境中的作用。本研究使用的数据来自癌症基因组图谱（The Cancer Genome Atlas）、基因表达总库（Gene Expression Omnibus）和 imvigor210 队列。我们发现，GJB3在LUAD患者中表达增加，并与LUAD分期相关。GJB3高表达的LUAD患者预后较差。在GJB3高表达组中，共有164条通路被显著激活。GJB3的表达与九种转录因子呈正相关，并可能受hsa-miR-6511b-5p的负调控。最后，我们发现免疫细胞浸润和免疫检查点的表达在 GJB3 高组和 GJB3 低组之间存在差异。综上所述。GJB3在LUAD患者中表现出高表达水平，GJB3表达升高的患者预后不良。此外，在 LUAD 患者中，GJB3 与免疫细胞浸润以及免疫检查点表达之间存在相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.